TargetMol

Ibiglustat (L-Malic acid)

Product Code:
 
TAR-T11599
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T11599-1mg1mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-5mg5mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-10mg10mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-25mg25mg£381.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-50mg50mg£532.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-100mg100mg£732.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ibiglustat (L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson?s disease, SRT in Fabry?s and Gaucher?s.
CAS:
1629063-78-0
Formula:
C24H30FN3O7S
Molecular Weight:
523.57
Pathway:
Metabolism
Purity:
0.9979
SMILES:
[C@H](CC(O)=O)(C(O)=O)O.C(NC(O[C@H]1C2CCN(C1)CC2)=O)(C)(C)C=3N=C(SC3)C4=CC=C(F)C=C4
Target:
Transferase

References

1. Glucosylceramide Synthase Inhibitors. WO 2015089067 A1. 2. Iva Stojkovska, et al. Molecular mechanisms of ?-synuclein and GBA1 in Parkinson?s disease. Cell Tissue Res. 2017. 3. Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9(14), 1687?1700. 4. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22.